multiple myeloma ash 2006 update jeffrey wolf, md director, myeloma program ucsf

MULTIPLE MYELOMA

ASH 2006 UPDATE

Jeffrey Wolf, MD

Director, Myeloma Program

UCSF

Myeloma ASH ReviewAbstracts to be covered

Abstract 795: Thal/Dex vs Dex frontline Abstract 57: Thal/Dex vs VAD frontline Abstract 796: Velcade/Dex frontline Abstract 56: Velcade/Dex vs VAD Abstract 798: Revlimid/Dex frontline Abstract 800: R-MP frontline Abstract 799: Revlimid/Dex (high dose) vs Revlimid/Dex

(lower dose) frontline Abstract 407: VMPT for relapse Abstract 404: Velcade/Doxil for relapse

WHAT SHOULD WE BE WHAT SHOULD WE BE LEARNING?LEARNING?

• Does the type of induction matter?Does the type of induction matter?

• Does CR matter? Does CR matter?

• Does transplant matter?Does transplant matter?

• What do we do for the non-transplant patient?What do we do for the non-transplant patient?

Thalidomide/Dex vs. DexThalidomide/Dex vs. Dex

Abstract #795Abstract #795

A Multicenter, Randomized, Double-Blind, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Thalidomide Plus Placebo-Controlled Study Thalidomide Plus

Dexamethasone Versus Dexamethasone Dexamethasone Versus Dexamethasone Alone As Initial Therapy For Newly Alone As Initial Therapy For Newly

Diagnosed Multiple Myeloma (MM 003)Diagnosed Multiple Myeloma (MM 003)

S. Vincent Rajkumar, Mohamad Hussein, John Catalano, S. Vincent Rajkumar, Mohamad Hussein, John Catalano, Wieslaw Jedrzejczak, Svetlana Sirkovich, Marta Olesnyckyj, Wieslaw Jedrzejczak, Svetlana Sirkovich, Marta Olesnyckyj,

Zhinuan Yu, Robert Knight, Jerry Zeldis, and Joan BladZhinuan Yu, Robert Knight, Jerry Zeldis, and Joan Bladéé

Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, Ohio; Frankston Mayo Clinic, Rochester, MN; Cleveland Clinic, Cleveland, Ohio; Frankston

Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Hospital, Frankston, Australia; Medical Academy of Warsaw, Warsaw, Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene Poland; Kiev Institution of Oncology of the UAMS, Kiev, Ukraine; Celgene

Corporation, Summit, NJ, and Hospital Clinic, Barcelona, Spain.Corporation, Summit, NJ, and Hospital Clinic, Barcelona, Spain.

Rajkumar et al. ASH 2006, abstract # 795

Thalidomide 50→200* mg d 1-28

Dex 40 mg, d 1-4, 9-12, 17-20

Placebo d 1-28Dex 40 mg, d 1-4, 9-12, 17-20

X 4 COURSES

TTP

Same exceptDex d 1-4

Continue until PD

OS

RR

Safety

Trial DesignTrial Design

* Thalidomide dose escalated in all patients, over 4 weeks, to improve tolerability


Response (RRC/IMWG)Response (RRC/IMWG) R

esp

on

se R

ate

(%)

* p=0.001

0

20

40

60

PR CR

69.4%*

Thalidomide/Dex

51.1%*

Placebo/Dex

PR+VGPR+CR

25.5%

8.1% *

35.3%

3.0% *

80 VGPR

35.7% *12.8% *

* CR+VGPR

p<0.0001


Common Non-Hematological ToxicitiesCommon Non-Hematological Toxicities

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0

EdemaEdema

AstheniaAsthenia

NeuropathyNeuropathy

PercentPercent

Thal/DexThal/DexGrade 3-4Grade 3-4Grade 1-2Grade 1-2 DexDex

Grade 3-4Grade 3-4Grade 1-2Grade 1-2

TremorTremor

InsomniaInsomnia

ConstipationConstipation


Major Grade 3/4 ToxicitiesMajor Grade 3/4 Toxicities

DVT/PE

Pneumonia

Hyperglycemia

Atrial Fibrillation

Cerebrovascular Ischemia

0 10 20 30 40 50

Percent

Thal/Dex (n=234) Dex (n=232)

Myocardial Ischemia

Any Grade 4


Time to ProgressionTime to Progression

P<0.0001

Thalidomide/dex median time to progression: 22.4 monthsPlacebo/dex median time to progression: 6.5 months

HR (95% CI)0.43 (0.32, 0.58)


Overall SurvivalOverall Survival

Thalidomide/Dex median overall survival: Not reachedPlacebo/Dex median overall survival: 32 months

HR (95% CI)0.82 (0.57, 1.16)


Thalidomide/Dex vs. VADThalidomide/Dex vs. VAD

Abstract #57Abstract #57

A randomized study of Thalidomide + Dexamethasone

(Thal/Dex) compared with Vincristine, Adriamycine and

Dexamethasone (VAD) as a pre-transplant treatment in

newly diagnosed Multiple Myeloma (MM)

M. Macro, M.Diviné, S.Chevret, J.P.Fermand

& all members of the “Myélome-autogreffe” group

Paris, Amiens, Caen, Créteil, Limoges, Strasbourg

FRANCE

Macro et al. ASH 2006, abstract # 57

VAD3 mthly courses

Infusional VAD

Thal + Dex 3 mths

Oral Thal/Dex

HD steroids

Randomization

Cytoxan (4g/m2) + G-CSF PBSC Collection

MLP 200 mg/m2

+ autologous PBSC transplantation

Stage II-III MM, <65 years


Thal/Dex vs VAD as Induction: Response


VAD 3 mthly courses

Thal/Dex 3 mths

R

MLP 200 mg/m2

CTX + G-CSF

MLP 200 mg/m2

CTX + G-CSF

VGPR RR (≥50%)

VAD 7.3% VAD 47% TD 24.7% TD 65%

Before PBSC mobilization

VGPR RR (≥50%)

VAD 41.7% VAD 62%TD 44.4% TD 68% At 6 mths post-transplant

VGPR RR (≥50%)

VAD 12.6% VAD 52% TD 34.7% TD 66% Before high-dose MLP

(p=.0027) (p=.01 )

(p=.002) (p=.04)

(p=.87) (p=.38)

VAD 3 mthly courses

Thal/Dex 3 mths

Thal/Dex vs VAD as a pre-transplant treatment in MM

Toxicity

Venous thrombosis and pulmonary embolism (no

proph)

7.5% (p=.004) 22.8%

Symptomatic peripheral neuropathy

12.9% (p=.42) 17.4 %

Any grade ≥ 2 side effect 27% (p=.07) 39%

Thal/Dex 3 mths


Velcade +/- DexVelcade +/- DexAbstract #796Abstract #796

Long-term follow-up of a phase 2 trial of bortezomib alone and in

combination with dexamethasone for the frontline treatment of

multiple myelomaS. Jagannath1, B. Durie1, J. Wolf1, E. Camacho1, D. Irwin1, J. Lutzky1, M. McKinley,1 E. Gabayan1,

A. Mazumder1, J. Crowley2, R. Vescio1

1Aptium Oncology Research Network, CA; 2Cancer Research and Biostatistics, WA

Jagannath et al. ASH 2006, abstract # 796

Cumulative Best Response (N = 49)

10 14 1826

2037

57

49

0

10

20

30

40

50

60

70

80

90

100

2 4 6

Cycles

Re

sp

on

se

ra

te (

%)

PRVGPRCR/nCR

BortezomibBortezomib

dexamethasone

49

7888

0%

20%

40%

60%

80%

100%

0 1 2 3 4 5 6Months After Registration

Bortezomib(Velcade)Events / N

40 / 49

Medianin Months

2

Median time to response: 1.9 months Responses assessed by EBMTR criteria with the addition of VGPR


OS In All Patients (N = 49)

Median follow-up 26.7 months Estimated 1- and 2-year survival rates: 92% and 85%

100%

80%

60%

40%

20%

0%0 12 24 36 48

Months after registration

Bortezomib (Velcade) 7/49 92% (83,100)

12-month

Deaths/N estimate


Velcade/Dex vs VAD

Abstract #56

56VELCADE/Dexamethasone (Vel/Dex) Versus VAD as

Induction Treatment Prior to Autologous StemCell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of

the IFM 2005-01 Randomized Multicenter Phase III Trial.

Jean-Luc Harousseau,1 Gerald Marit,2 Denis Caillot,3 Philippe Casassus,4 Thierry Facon,5 Mohamad Mohty,6 Frederic Maloisel,7

Herve Maisonneuve,8 Carine Chaleteix,9 Lofti Benboubker,10 Dixie-Lee Esseltine,11 Michel Attal.12

1Hematology, Hôpital Hotel-Dieu, Nantes, France; 2CHU Bordeaux, Pessac, Bordeaux, France; 3Hematology Unit, Hôpital Bocage, Dijon, France; 4Hôpital

Avicenne, Bobigny, Paris, France; 5Hôpital Claude-Huriez, Lille, France; 6Institute Paoli-Calmettes, Marseille, France; 7Hôpital Civil, Strasbourg, France; 8CHD La Roche Sur Yon, La Roche Sur Yon, Vendee, France; 9CHU Clermont-Ferrand,

Clermont-Ferrand, Auvergne, France; 10Hematology and Cell Therapy Unit, CHRU Tours, Tours, France; 11Millennium Pharmaceuticals Inc, Cambridge, MA,

USA; 12Hôpital Purpan, Toulouse, France.

Vel/Dex vs. VAD Induction in Newly Diagnosed MM: Preliminary Analysis of IFM 2005-01 Trial

Treatment Scheme:

Second ASCT or RIC allo if <VGPR

Arm A1: VADArm A2: VAD + DCEP

ASCT

Induction ± Consolidation

Transplant 1

A B

Randomization Stratification for β2 microglobulin and Ch 13 abnormalities

Arm B1: Vel/DexArm B2: Vel/Dex + DCEP

ASCT

Harousseau et al. ASH 2006, abstract # 56


By Induction Therapy By Consolidation Therapy

VAD (A1+A2)

N=82

Vel/Dex (B1+B2)

N=79

No DCEP(A1+B1)

N=78

DCEP(A2+B2)N=64

CR/nCR 9% 20% 11% 28%

CR 4% 9% 3% 14%

VGPR 17% 23% 26% 13%

CR+VGPR 26% 43% 37% 41%

PR (incl VGPR) 59% 62% 68% 61%

CR+PR 67% 82% 79% 89%

Response: by investigator assessment; evaluated by modified EBMT criteria



Efficacy: Impact of baseline characteristics on post-induction response (preliminary analysis)

CR/nCR rateCharacteristic VAD (A1+A2) Vel/Dex (B1+B2)

β2M level

>3 mg/L 4/43 (9%) 8/41 (20%)

Del(13)

Yes 4/37 (11%) 9/36 (25%)

β2M, beta-2-microglobulin; Del(13), chromosome 13 deletion



VAD (A1+A2)

N=70

Vel/Dex(B1+B2)

N=68

TOTAL

N=138

Median CD34+ cells collected (x106/kg) 8.7 6.3 7.5

ITT pop receiving 1st ASCT, n (%) 58 (71%) 58 (73%) 116 (72%)

Median time to ANC ≥ 0.5 x 109/L, days 7 7 7

Median time to platelet count ≥ 20 x 109/L, days

1 1 1

Patients not requiring 2nd ASCT

n (%)32 (55) 45 (78) 77 (66)

Stem Cell Transplant: Preliminary data



VAD (A1+A2) N=81

Vel/Dex (B1+B2) N=81

Overall:

Gr ≥ 3 AE, n (%) 29 (36%) 24 (30%)

Gr ≥ 4 AE, n (%) 8 (10%) 7 (9%)SAE, n (%) 14 (17%) 12 (15%)Death, n (%) 1 (1%) 1 (1%)

By Event:Neutropenia (Gr 3/4) 7% 4%Fever/infection (all grades) 17% 14%Mucositis (Gr 3/4) 10% 1%

Neurologic toxicity (including PN, paraesthesias, and dysaesthesias)

Gr 1/2: 7%Gr 3/4: 0

Gr 1/2: 23%Gr 3/4: 4%

Thrombosis (all grades) 4% 2%

Safety: No sig difference between 2 arms


What have We Learned?

The use of Vel/Dex over VAD results in fewer patients needing a 2nd transplant

The use of TD is more toxic than VAD (DVT’s and VTE’s) and results in similar outcomes post transplant

Percent of Patients who Achieved

VGPR

Vel/Dex

78%

VAD

55%

TD

44%

VAD

42%

Revlimid/DecadronFrontline

Abstract # 798

Results: Response to TherapyAll 34 pts assessed prior to transplant or any other therapy

All Patients No Transplant

Objective Response Rate

91%

CR 18% 24%

VGPR 38% 43%

PR 35%

Lacy et al. ASH 2006, abstract # 798

Toxicity > Grade 3

fatigue (21%) neutropenia (21%) anxiety (6%) pneumonitis (6%)

muscle weakness (6%) rash (6%) pulmonary embolism

(3%) with ASA prophylaxis


Time in Months

Pro

po

rtio

n P

rog

ress

ion

-fre

e a

nd

Aliv

e

0 5 10 15 20 25

0.0

0.2

0.4

0.6

0.8

1.0

No TransplantTransplant

Progression Free Survival

2 yr PFS rate

83%

59%


Time in Months

Pro

po

rtio

n A

live

0 5 10 15 20 25

0.0

0.2

0.4

0.6

0.8

1.0

No TransplantTransplant

Overall Survival

2 yr OS rate

90%

92%


OS for 2 Novel agents in Newly Diagnosed MM in Combo with Dex: No Transplant

Rev/Dex: Lacy et al Vel/Dex: Jagannath et al

Revlimid/Melphalan/PrednisoneNewly Diagnosed

Abstract #800

1 2 3 4 21

Revlimid® 5–10 mg daily

Mel 0.18–0.25 mg/Kg

Prednisone 2 mg/Kg

Every 4–6 weeks for a maximum of 9 cycles

day

6 patients in each cohort with additional 15 pts in cohort 3 and 4

6+15100.25Cohort 4

6+15100.18Cohort 3

650.25Cohort 2

650.18Cohort 1

PatientsRevlimid® mg/dMelphalan mg/Kg/d

RMP: Treatment Schedule

Palumbo et al. ASH 2006, abstract # 800

Dose Limiting Toxicity

3/61/60/60/6Pts with DLT

1/6

1/6

1/6

Cutaneous GR 3

Thrombosis GR 4

Metabolic GR 3

2/6Delay at cycle 2

1/6Neutropenic fever

1/6Severe Neutropenia

Cohort 40.25–10

Cohort 30.18–10

Cohort 20.25–5

Cohort 10.18–5DLT at Cycle 1


R-MP R-MP Cohort 3 (0.18-10)Cohort 3 (0.18-10)

Best ResponseBest Responsen=21n=21

MPT MPT Best ResponseBest Response

n=129*n=129*

*Historical control – Palumbo et al, Lancet 2006 *Historical control – Palumbo et al, Lancet 2006 5.4% of response not available5.4% of response not available

Pro

po

rtio

n o

f p

atie

nts

Pro

po

rtio

n o

f p

atie

nts

Pro

po

rtio

n o

f p

atie

nts

Pro

po

rtio

n o

f p

atie

nts

R-MP vs MPT: Response Rates R-MP vs MPT: Response Rates

24 24

33

19

0 00

10

20

30

40

50

60

70

CR VGPR PR MR SD PD

48%48%

16

21

40

5 58

0

10

20

30

40

50

60

70

CR VGPR PR MR SD PD

37%37%


MPT: median follow-up 17.6 months (0.23-44.3) [N=129]*MPT: median follow-up 17.6 months (0.23-44.3) [N=129]*

R-MP: median follow-up 14.6 months (10.8-21.8) [N=53]R-MP: median follow-up 14.6 months (10.8-21.8) [N=53]

p=0.046p=0.053

R-MP vs MPT: EFS and OS

EFS OS

*Historical control – Palumbo et al, Lancet 2006 *Historical control – Palumbo et al, Lancet 2006 Palumbo et al. ASH 2006, abstract # 800

MPT Superior to MP

Previous Studies

Melphalan/Velcade/Prednisone (MVP)

Previous Study

Melphalan + Velcade + Prednisone(MVP)

12 of 16 CR patients tested for minimal residual disease; 6/12 (50%) achieved an immunophenotypic remission

Historical response with MP: 42% nCR + PR Hernandez, BJH, 2004

No DLTs observed in Phase I Phase II: 20% G4 myelosuppression

Phase II trial accruing, goal of 60 pts, dose will be 1.3 mg/m2

Response* (n = 53)

Bortezomib + Melphalan + Prednisone

CR 32%

nCR 11%

PR 45%

CR + PR 89%

* Modified EBMT criteria

Mateos et al. Blood, June, 2006

Newly Diagnosed

Response to Therapy

Revlimid/High Dose Dex vsRevlimid/Lower Dose Dex

Abstract #799

A Randomized Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone Versus

Lenalidomide Plus Low-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative

Oncology Group

S. Vincent Rajkumar, Susanna Jacobus, Natalie Callander, Rafael Fonseca, David Vesole, Philip Greipp

Mayo Clinic, Rochester, MN; Dana Farber Cancer Institute, Boston, MA;

University of Wisconsin, Madison, WI; Mayo Clinic Arizona, Scottsdale, AZ; St. Vincents Hospital, New

York, NY

RRAANNDDOOMMIIZZAATTIIOONN

Len + DexLen + Dexx4 cyclesx4 cycles(40 mg d1-4,(40 mg d1-4,9-12, 17-20)9-12, 17-20)

SchemaSchema

CR/PRCR/PR

Less Less than than PRPR

@ 4 months@ 4 monthsPts eligible for Pts eligible for SCT SCT proceed to SCT*proceed to SCT*

Thal + Thal + Dex Dex x 4 cyclesx 4 cycles

445 pts

Len + Low Len + Low dose Dex dose Dex x 4 cyclesx 4 cycles(40 mg wkly(40 mg wklyD1,8,15,22)D1,8,15,22)

CR/PR/StableCR/PR/Stable


Serious adverse eventsSerious adverse eventsToxicityToxicity

Arm AArm A

(N=223)(N=223)

Arm BArm B

(N=222)(N=222)P valueP value

Infection/Pneumonia (Grade Infection/Pneumonia (Grade >=3)>=3) 16.1%16.1% 9.0%9.0% 0.0310.031

Fatigue (Grade >=3)Fatigue (Grade >=3) 11.7%11.7% 4.1%4.1% 0.0040.004

Hyperglycemia (Grade >=3)Hyperglycemia (Grade >=3) 5.8%5.8% 2.3%2.3% 0.0900.090

DVT/PE (Grade >=3)DVT/PE (Grade >=3) 18.4%18.4% 6.3%6.3% <0.001<0.001

Atrial fibrillation/flutter Atrial fibrillation/flutter (Grade>=3)(Grade>=3) 3.1%3.1% 0.0%0.0% 0.0150.015

Neuropathy (Grade >=3)Neuropathy (Grade >=3) 0.4%0.4% 1.4%1.4% 0.3720.372

Any non Hem toxicity (Grade Any non Hem toxicity (Grade >=3)>=3) 54.3%54.3% 39.6%39.6% 0.0020.002

Toxicity of Any Type (Grade Toxicity of Any Type (Grade >=4)>=4) 19.3%19.3% 11.3%11.3% 0.0250.025

Death (Grade 5)Death (Grade 5) 4.9%4.9% 0.5%0.5% 0.0060.006Rajkumar et al. ASH 2006, abstract # 799

Bortezomib (VelcadeBortezomib (Velcade®®)), Melphalan, , Melphalan, Prednisone and Thalidomide (VMPT) in Prednisone and Thalidomide (VMPT) in

Advanced Multiple MyelomaAdvanced Multiple Myeloma

Results of a Multicenter Phase I/II Results of a Multicenter Phase I/II StudyStudy

Antonio PalumboAntonio PalumboDiv. Hematology, University of Torino

Abstract 407

V-MPT at 1° RelapseV-MPT at 1° RelapseMPT at DiagnosisMPT at Diagnosis

V-MPT (N=14) MPT (N=129)^

0%

21%21%21%

36%

05

101520253035404550

CR- VGPR PR MR SD-PD

%

36%36%

13%

5%

39%

21%

15%

0

5

10

15

20

25

30

35

40

45

CR- VGPR PR MR SD-PD

%

^Palumbo et al,Lancet 2006;367:825

57%57%

Diagnosis1° Relapse

Study design: VMPT vs VMPStudy design: VMPT vs VMP

R

VMPT 9 courses

MaintenanceVelcade

Thalidomide

VMP9 courses

None

At diagnosis

End points: PFS, OS, RR, Safety

Retrospective Analysis of Re-Retrospective Analysis of Re-Treatment Treatment

With BortezomibWith Bortezomib

Conner T et al. Blood 2006;108:1007a [abstract 3531]

Initial Bortezomib Treatment Bortezomib Re-treatment

VGPR (n=2) VGPR (n=16) PR (n=5)

<PR (n=9)

VGPR (n=1) PR (n=22) PR (n=4)

<PR (n=17)

VGPR (n=1) <PR (n=24) PR (n=2)

<PR (n=21)

ORR 44%

ORR 23%

ORR 13%

PotpouriPotpouri

New Agents for MyelomaNew Agents for MyelomaClinical (1)Clinical (1)

Abstract Abstract ##

CategoryCategory CompoundCompound PhasePhase InstitutionInstitution

InvestigatorInvestigator

BiopharmBiopharm ResultResult

406406 Hsp 90 Hsp 90 Inh (17 Inh (17 AAG)AAG)

TanespimycinTanespimycin

(KOS-953) (KOS-953) + BZ+ BZ

II RichardsonRichardson

et.al.et.al.

KosanKosan

35743574 Anti-Anti-CD56CD56

BB-10901BB-10901 II Chanan - Chanan - KhanKhan

ImmunogeImmunogenn

activeactive


HCD122 HCD122 (formerly (formerly Chir-12.12)Chir-12.12)

II BensingerBensinger NovartisNovartis activeactive


SGN-40SGN-40 II HusseinHussein Seattle-Seattle-GeneticsGenetics

+/-+/-

activeactive

New Agents New Agents ForFor Myeloma MyelomaClinical (2)Clinical (2)

Abstract Abstract ##

CategoryCategory CompoundCompound PhasePhase InstitutionInstitution


BiopharmBiopharm ResultsResults

35793579 Hsp90 Hsp90 InhInh

IPI-504IPI-504 II SiegelSiegel

HackensackHackensack

etcetc

InfinityInfinity Too Too EarlyEarly

35803580 P38 P38 MAP-MAP-

Kinase Kinase InhInh

Scio-469Scio-469 IIII Siegel etcSiegel etc SciosScios Requires Requires BZBZ

35823582 Akt InhAkt Inh Perifosine Perifosine (KRX-0401(KRX-0401

IIII Richardson, Richardson, etcetc

KeryxKeryx Requires Requires Dex or Dex or

BZBZ

35833583 HDAC HDAC InhInh

PXD 101PXD 101 IIII Moffitt, etcMoffitt, etc CuragenCuragen Requires Requires

Dex Dex

New Agents for MyelomaNew Agents for MyelomaPre-Clinical (1)Pre-Clinical (1)

Abstract #Abstract # CategoryCategory CompoundCompound InstitutionInstitution


BiotechBiotech

244244 Antiangio- Antiangio-

PI-3 kinase PI-3 kinase inhibitorinhibitor

SF 1126SF 1126 LonialLonial SemaforeSemafore

IndianapolisIndianapolis

841841 Notch Sig. Notch Sig. InhibitorInhibitor

Gamma Gamma Secretase Inh. Secretase Inh.

(GSI)(GSI)

MoffittMoffitt --

26042604 HDACHDAC

InhibitorInhibitor

UCL 67022UCL 67022 St. Bart’sSt. Bart’s --

34833483 HDACHDAC

InhibitorInhibitor

PXD 101PXD 101 BerensonBerenson CuragenCuragen

34273427 CD40CD40

LigandLigand

CD40L, CD40L, CD154CD154

BaylorBaylor --

New Agents for MyelomaNew Agents for MyelomaPre-Clinical (2)Pre-Clinical (2)

Abstract #Abstract # CategoryCategory CompoundCompound InstitutionInstitution


BiotechBiotech

34523452 B-cell Act B-cell Act Factor InhFactor Inh

(BAFF)(BAFF)

AMG 523AMG 523 FarberFarber AmgenAmgen

34603460 ERK ½ InhERK ½ Inh AZD 6244AZD 6244 FarberFarber --

34613461 Irreversible Irreversible Proteasome Proteasome

InhInh

PR-171PR-171 UNCUNC ProteolixProteolix

34623462 Organic Organic ArsenicArsenic

Z10-101Z10-101 Gale Gale BerensonBerenson

ZiopharmZiopharm

34813481 Proteasome Proteasome Inh.( Oral)Inh.( Oral)

MultipleMultiple -- ProteolixProteolix

multiple myeloma ash 2006 update jeffrey wolf, md director, myeloma program ucsf

Documents

dex abstract

diagnosed abstract

relapse abstract

revlimiddex frontline

velcadedex frontline

relapse slide

rmp frontline abstract

velcadedex vs vad abstract